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Ruben J. Boado1,2, Jeff Zhiqiang Lu1, Eric K.-W. Hui1, Rachita K. Sumbria2, and William M.
Pardridge2
1ArmaGen Technologies, Inc., Santa Monica, CA 90401
2UCLA,
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Abstract
NIH-PA Author Manuscript

Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder of the brain caused by
mutations in the gene encoding the lysosomal sulfatase, arylsulfatase A (ASA). It is not possible to
treat the brain in MLD with recombinant ASA, because the enzyme does not cross the blood-brain
barrier (BBB). In the present investigation, a BBB-penetrating IgG-ASA fusion protein is
engineered and expressed, where the ASA monomer is fused to the carboxyl terminus of each
heavy chain of an engineered monoclonal antibody (MAb) against the human insulin receptor
(HIR). The HIRMAb crosses the BBB via receptor-mediated transport on the endogenous BBB
insulin receptor, and acts as a molecular Trojan horse to ferry the ASA into brain from blood. The
HIRMAb-ASA is expressed in stably transfected Chinese hamster ovary cells grown in serum free
medium, and purified by protein A affinity chromatography. The fusion protein retains high
affinity binding to the HIR, EC50 = 0.34 ± 0.11 nM, and retains high ASA enzyme activity, 20 ± 1
units/mg. The HIRMAb-ASA fusion protein is endocytosed and triaged to the lysosomal
compartment in MLD fibroblasts. The fusion protein was radio-labeled with the Bolton-Hunter
reagent, and the [125I]-HIRMAb-ASA rapidly penetrates the brain in the Rhesus monkey
following intravenous administration. Film and emulsion autoradiography of primate brain shows
global distribution of the fusion protein throughout the monkey brain. These studies describe a
new biological entity that is designed to treat the brain of humans with MLD following noninvasive, intravenous infusion of an IgG-ASA fusion protein.
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Introduction
Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder caused by mutations
in the gene encoding the arylsulfatase A (ASA) enzyme (Fluharty, 2006). ASA deficiency in
the brain leads to sulfatide glycolipid accumulation in the brain (Molander-Melin et al,
2004; Blomqvist et al, 2011). The most common form of MLD is the infantile form, and
afflicted children suffer from severe abnormalities of the central nervous system (CNS),
including gait disturbances, convulsions, and dementia, and die before 5 years of age
(Fluharty, 2006). A potential treatment for MLD is enzyme replacement therapy (ERT) with
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recombinant ASA. However, ERT is not effective for the CNS, because the ASA enzyme
does not cross the blood-brain barrier (BBB) (Matzner et al, 2005). To circumvent the BBB,
the recombinant ASA enzyme has been administered by the intra-thecal route with direct
injection into the cerebrospinal fluid (CSF) of mice (Stroobants et al, 2011). Whereas, the
CSF route may deliver adequate amounts of enzyme to the brain in small animals, such as
the mouse, there is little penetration into the brain from CSF in large animals. The intrathecal injection of a massive amount, 960 mg, of a lysosomal enzyme, acid
sphingomyelinase, in the Rhesus monkey resulted in distribution only to the ependymal
surface of the brain (Ziegler et al, 2011). Drug penetration into the brain from the CSF is
limited by diffusion, which is slow compared to the rapid rate of CSF exit from brain to
blood via bulk flow (Pardridge, 2005).
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The entire volume of the human brain can be treated by delivery of ASA via the transvascular route across the BBB. However, this approach requires the re-engineering of ASA
as a molecule that is BBB-penetrating. This is possible with molecular Trojan horse (MTH)
technology, which involves genetic fusion of ASA to another protein that does cross the
BBB (Pardridge and Boado, 2012). A MTH is an endogenous peptide or peptidomimetic
monoclonal antibody (MAb) that crosses the BBB via receptor-mediated transport. The most
active MTH is a genetically engineered MAb against the human insulin receptor (HIR). The
HIRMAb cross reacts with the insulin receptor of Old World primates such as the Rhesus
monkey, but not with the insulin receptor of New World monkeys (Pardridge et al, 1995) or
the mouse (Zhou et al, 2012). The purpose of the present investigation was first the genetic
engineering, host cell expression, and biochemical validation of a fusion protein of the
HIRMAb and human ASA. The amino terminus of the mature ASA is fused to the carboxyl
terminus of each heavy chain of the HIRMAb, and this fusion protein is designated the
HIRMAb-ASA fusion protein (Figure 1). The dimeric configuration of the ASA domain of
the fusion protein replicates the normal dimeric configuration of ASA at neutral pH
(Lukatela et al 1998). The second goal of the present study was to characterize the plasma
pharmacokinetics, and brain uptake of the HIRMAb-ASA fusion protein in vivo in the
Rhesus monkey. The study shows the HIRMAb-ASA fusion protein retains both high
affinity binding to the HIR and high ASA enzyme activity, and is rapidly transported across
the primate BBB in vivo.

Materials and Methods
Engineering of tandem vector and production of CHO line
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A 1.5 kb cDNA encoding the human ASA cDNA was produced by reverse transcriptase
polymerase chain reaction using the following forward and reverse oligodeoxynucleotide
primers: 5′-phosphate-CCCGTCCGCCCAACATCGTGCT-3′ and 5′-phosphateTCAGGCATGGGGATCTGGGCAATG-3′, and polyA+RNA from human liver. The ASA
sequence, absent the enzyme signal peptide, was fused to the carboxyl terminus of the CH3
region of the heavy chain (HC) of the chimeric HIRMAb. A tandem vector was engineered
in which the expression cassettes encoding this fusion HC, as well as the HIRMAb light
chain (LC), and the murine dihydrofolate reductase, were placed on a single plasmid DNA
(Boado et al, 2007). DNA sequencing showed the 3 expression cassettes spanned 10,003
nucleotides. The light chain was comprised of 234 amino acids (AA), which included a 20
AA signal peptide. The predicted molecular weight of the light chain is 23,398 Da with a
predicted isoelectric point (pI) of 5.45. The fusion protein of the HIRMAb heavy chain and
ASA was comprised of 953 AA, which included a 19 AA signal peptide, the 443 AA
HIRMAb heavy chain, a 2 AA linker (Ser-Ser), and the 489 AA mature ASA enzyme. The
predicted pI of the heavy chain is 6.43, and the predicted molecular weight of the heavy
chain, without glycosylation, is 100,637 Da, which includes 51,900 Da within the ASA
domain. The AA sequence of the ASA domain is 100% identical with the sequence of
Biotechnol Bioeng. Author manuscript; available in PMC 2014 February 10.
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mature human ASA (Genbank NP_000478). The predicted molecular weight of the heterotetramer, without glycosylation, is 248,035 Da.
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The tandem vector plasmid DNA was linearized and CHO cells, adapted to serum free
medium (SFM), were electroporated with the tandem vector, selected with G418 and
hypoxanthine-thymine deficient medium, and amplified with graded increases of
methotrexate up to 80 nM. The CHO line underwent 2 successive rounds of 1 cell/well
dilutional cloning, and positive clones were selected by measurement of medium human IgG
concentrations by enzyme-linked immunosorbent assay (ELISA). The CHO line was stable
through multiple generations, and produced medium IgG levels of 10 mg/L in shake flasks
at a cell density of 1–2 million cells/mL in SFM.
Purification and analysis of fusion protein
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The CHO cells were propagated in 1 L bottles, until 2.4L of conditioned SFM was collected.
The medium was ultra-filtered with a 0.2 um Sartopore-2 sterile-filter unit (Sartorius Stedim
Biotech, Goettingen, Germany), and applied to a 25 mL protein A Sepharose 4 Fast Flow
(GE Life Sciences, Chicago, IL) column equilibrated in 25 mM Tris/25 mM NaCl/5 mM
EDTA/pH=7.1. Following application of the sample, the column was washed with 25 mM
Tris/1 M NaCl/5 mM EDTA/pH=7.1, and the fusion protein was eluted with 0.1 M sodium
acetate/pH=3.7. The acid eluate was pooled, Tris base was added to raise the pH to 5.5,
NaCl was added to 0.15 M, and the solution was stored sterile-filtered at 4C or −70C.
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The identity of the HIRMAb-ASA fusion protein was verified by human IgG and human
ASA Western blotting. For the human IgG Western blot, the primary antibody was a goat
anti-human IgG (H+L) (Vector Labs, Burlingame, CA). For the human ASA Western blot,
the primary antibody was a mouse anti-human ASA antibody (R&D Systems, Minneapolis,
MN). The secondary antibody was a biotinylated horse anti-goat IgG or biotinylated horse
anti-mouse IgG antibody (Vector Labs). The purity of the HIRMAb-ASA fusion protein was
verified by reducing sodium dodecylsulfate polyacrylamide gel electrophoresis (SDSPAGE) using a 4–15% gradient gel. The prestained molecular weight (MW) standards were
obtained from Fermentas (Glen Burnie, MD). The potency of the HIRMAb-ASA fusion
protein was evaluated by measurement of the affinity of binding of the fusion protein to the
HIR extracellular domain (ECD) using an ELISA. The HIR ECD was purified from the
serum free conditioned medium produced by a stably transfected CHO line using lectin
affinity chromatography, as described previously (Boado et al, 2007). ASA enzyme activity
was measured using a spectrophotometric enzymatic assay using 4-nitrocatechol sulfate as
the substrate at pH=5.0 at 37°C (Baum et al, 1955). The formation of 4-nitro catechol was
followed by measurement of absorbance at 515 nm. The ASA enzyme activity was reported
as units/mg protein where 1 unit=1 umol/min.
HIRMAb-ASA fusion protein uptake by MLD fibroblasts
MLD fibroblasts (GM00243) were obtained from the Coriell Institute for Medical Research
(Camden, NJ), were grown overnight in DMEM with 10% FBS to >80% confluency in LabTek chamber slide plates (Thermo Scientific, Rochester, NY). The medium was aspirated,
the wells washed well with PBS, and the cells were treated with fresh DMEM with no serum
and containing 10 ug/mL of the HIRMAb-ASA fusion protein. Following a 24 hr incubation
at 37C, the medium was aspirated, the wells washed extensively with cold PBS, and the
cells were fixed with 100% cold methanol for 40 min at −20C. Following a PBS wash, the
plates were blocked with 10% donkey serum, and then co-labeled with 10 ug/mL of a goat
anti-ASA antibody (R&D Systems), and 10 ug/ml of a mouse MAb to human lysosomal
associated membrane protein (LAMP)-1 (Santa Cruz Biotechnology, Santa Cruz, CA).
Negative control antibodies were the same concentrations of either goat or mouse IgG. The
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secondary antibodies (Molecular Probes/Invitrogen, Carlsbad, CA) were 5 ug/mL each of
Alexa Fluor-488 conjugated donkey anti-mouse IgG (green channel) and Alexa Fluor-594
conjugated donkey anti-goat IgG (red channel). The washed slides were mounted with
Vectashield mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) (Vector
Labs). Confocal microscopy was performed with a Leica TCS SP2 AOBS inverted
fluorescence microscope with a Leitz P1 Apo 100X oil immersion objective and a Leica
confocal laser scanning adapter utilizing argon (476 and 488 nm), new diode (561 nm) and
helium-neon (633 nm) lasers, respectively. Optical sections (1 um, resolution 300 nm) were
obtained sequentially through the z-plane of each sample.
Rhesus monkey brain uptake and pharmacokinetics
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The HIRMAb-ASA fusion protein was radiolabeled with [125I]-Bolton-Hunter reagent
(American Radiolabeled Chemicals, St. Louis, MO), which had a specific activity of 2200
uCi/nmol. Prior to labeling, the fusion protein was buffer exchanged with 0.01 M sodium
acetate/140 mM NaCl/pH=5.5/0.001% Tween-80 and an Amicon Ultra-15 centrifugal filter
unit (EMD Millipore, Billerica, MA). The labeled HIRMAb-ASA fusion protein was
purified by gel filtration with a 1×28 cm column of Sephadex G-25 and an elution buffer of
0.01 M sodium acetate/140 mM NaCl/pH=5.5/0.001% Tween-80. An adult male Rhesus
monkey, 8.2 kg, was investigated at MPI Research (Mattawan, MI). The animal was injected
intravenously (IV) with 2042 uCi of [125I]-HIRMAb-ASA fusion protein by bolus injection
over 30 seconds in the left femoral vein. The injection dose (ID) of the HIRMAb-ASA
fusion protein was 55 ug/kg. The animal was anesthetized with intramuscular ketamine. All
procedures were carried out in accordance with the Guide for the Care and Use of
Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health.
Following intravenous drug administration, femoral venous plasma was obtained at 2, 5, 15,
30, 60, 90, and 120 min for determination of total plasma [125I] radioactivity (DPM/mL) and
plasma radioactivity that is precipitated by 10% cold trichloroacetic acid (TCA). The animal
was euthanized, and samples of major organs (heart, liver, spleen, lung, skeletal muscle, and
omental fat) were removed, weighed, and processed for determination of radioactivity. The
cranium was opened and the brain was removed. Samples of frontal cortical gray matter,
frontal cortical white matter, cerebellar gray matter, cerebellar white matter, and choroid
plexus were removed for radioactivity determination.
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Samples (~2 gram) of frontal cortex were removed for capillary depletion analysis to
confirm transport of the HIRMAb-ASA fusion protein across the BBB. The capillary
depletion method separates the vascular tissue in brain from the post-vascular compartment
(Triguero et al, 1990). Based on measurements of the specific activity of brain capillaryspecific enzymes, such as γ-glutamyl transpeptidase or alkaline phosphatase, the postvascular supernatant is >95% depleted of brain vasculature (Triguero et al, 1990). To
separate the vascular and post-vascular compartments, the brain was homogenized in 8 mL
cold PBS in a tissue grinder. The homogenate was supplemented with 8 mL cold 40%
dextran (70 kDa, Sigma Chemical Co.), and an aliquot of the homogenate was taken for
radioactivity measurement. The homogenate was centrifuged at 3200 g at 4C for 10 min in a
fixed angle rotor. The brain microvasculature quantitatively sediments as the pellet, and the
post-vascular supernatant is a measure of capillary depleted brain parenchyma (Triguero et
al, 1990). The vascular pellet and supernatant were counted for 125I radioactivity in parallel
with the homogenate. The volume of distribution (VD) was determined for each of the 3
fractions from the ratio of total [125I] radioactivity in the brain fraction (DPM/gram brain)
divided by the total [125I] radioactivity in the 120 min terminal plasma (DPM/uL plasma).
The percent of radioactivity in the post-vascular supernatant that was precipitable with 10%
cold TCA was determined. Plasma and tissue samples were analyzed for 125I radioactivity
with a Wizard model 1470 gamma counter (Perkin Elmer, Shelton, CT).

Biotechnol Bioeng. Author manuscript; available in PMC 2014 February 10.
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The TCA precipitable [125I] radioactivity in plasma, DPM/mL, was converted to % injected
dose (ID)/mL, and the %ID/mL was fit to a bi-exponential equation,
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The intercepts (A1, A2) and the slopes (k1, k2) were used to compute the median residence
time (MRT), the central volume of distribution (Vc), the steady state volume of distribution
(Vss), the area under the plasma concentration curve (AUC), and the systemic clearance
(CL), as described previously (Pardridge et al, 1995). Non-linear regression analysis used
the AR subroutine of the BMDP Statistical Software (Statistical Solutions Ltd, Cork,
Ireland). Data were weighted by 1/(%ID/mL)2.
The BBB permeability-surface area (PS) product was computed from the brain uptake at 2
hours, %ID/gram, divided by the 2 hour plasma AUC, %ID·min/mL, and reported as uL/
min/gram.
Brain autoradiography
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The fresh brain was cut into coronal slabs, and immediately frozen in liquid nitrogen. Frozen
sections (20 um) were cut with a cryostat at −15°C; the sections were air dried and exposed
to Kodak Biomax MR X-ray film (Carestream Health, Rochester, MN) for up to 7 days
followed by x-ray film development. The films were scanned and the image was saved in
Photoshop, and colorized with NIH Image software. Frozen sections of brain were also
subbed to slides coated with HyperCoat LM-1 emulsion (GE Amersham, Chicago, IL); the
slides were developed in the dark for 8 weeks, and processed with D-19 developer and fixer
(Kodak, Rochester, NY). The unstained slides were examined with light microscopy under
either dark field or bright field illumination with a Nikon Microphot FXA microscope and
100X, 200X, and 400X magnification. Digital images were taken with an Optixcam Summit
OCS-13 digital microscope camera and transferred to Adobe Photoshop 6.0.

Results

NIH-PA Author Manuscript

The CHO-derived HIRMAb-ASA fusion protein was purified by protein A affinity
chromatography to homogeneity on SDS-PAGE (Figure 2). The HIRMAb-ASA fusion
protein and the chimeric HIRMAb use the same LC, which migrates with a molecular
weight (MW) of 27 kDa, whereas the size of the HC of the HIRMAb-ASA fusion protein,
124 kDa, is larger than the size of the HC of the HIRMAb, 56 kDa (Figure 2), owing to
fusion of the ASA to the antibody HC. The anti-human IgG antibody reacts with the LC and
HC of both the HIRMAb and the HIRMAb-ASA fusion protein (Figure 3, left panel). The
anti-human ASA antibody reacts only with the HC of the HIRMAb-ASA fusion protein, but
not with the HC of the HIRMAb (Figure 3, right panel).
The affinity for binding to the HIR of the HIRMAb-ASA fusion protein is comparable to the
affinity of binding of the HIRMAb. The EC50 of the HIRMAb-ASA fusion protein binding
to the HIR, 0.34 ± 0.11 nM, is equal to the EC50, 0.23 ± 0.06 nM, of the HIRMAb binding
to the HIR (Figure 4). The ASA enzyme specific activity of the HIRMAb-ASA fusion
protein was 20 ± 1 umol/min/mg protein, as measured with the spectrophotometric assay
(Methods).
MLD fibroblasts were incubated with 10 ug/mL HIRMAb-ASA fusion protein for 24 hours
followed by fixation and immune labeling with a mouse monoclonal antibody to LAMP1, a
lysosomal marker, and a goat polyclonal antibody to human ASA. The LAMP1
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immunoreactivity within the cell is detected in the green channel (Figure 5A), and the ASA
immunoreactivity is detected in the red channel (Figure 5B). The overlap of the ASA and
LAMP1 immunoreactivity is shown in Figure 5C. There was no immunoreactivity in the
cells labeled with mouse or goat isotype control antibodies.
The HIRMAb-ASA fusion protein was radio-labeled with the [125I]-Bolton-Hunter reagent
to a specific activity of 4.5 uCi/ug and a TCA precipitation of 99%. The [125I]-HIRMAbASA fusion protein (2042 uCi, 450 ug) was injected IV in an 8.2 kg male Rhesus monkey.
The time course of plasma radioactivity is shown in Figure 6, which is expressed either as
%ID/mL (Figure 6A) or ng/mL (Figure 6B). The percent of total plasma radioactivity that
was precipitable by TCA was 98 ± 1%, 97 ± 1%, 88 ± 1%, 65 ± 1%, 45 ± 2%, 43 ± 2%, and
42 ± 2%, respectively at 2, 5, 15, 30, 60, 90, and 120 min after IV injection. The plasma
profile of TCA-precipitable radioactivity was fit to a 2-exponential equation (Methods) to
yield the pharmacokinetics (PK) parameters shown in Table I. The [125I]-HIRMAb-ASA
fusion protein is rapidly cleared from blood with a mean residence time of 59 ± 12 minutes,
a systemic volume of distribution (Vss) that is 5-fold greater the central compartment
volume (Vc), and a high rate of systemic clearance, 3.9 ± 0.2 mL/min/kg (Table I).
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The volume of distribution (VD) of the HIRMAb-ASA fusion protein in brain homogenate
at 2 hours after injection is high, 526 ± 23 uL/gram, compared to the brain VD of a nonspecific human IgG1 isotype control antibody, 20 ± 6 ul/gram (Table II). The brain VD of
the IgG1 isotype control antibody represents the brain uptake of a molecule that is
sequestered within the blood volume of brain, and which does not cross the BBB. The high
brain VD for the HIRMAb-ASA fusion protein indicates the fusion protein is either
sequestered by the brain vasculature, or has penetrated the BBB and entered brain
parenchyma. The VD of the HIRMAb-ASA fusion protein in the post-vascular supernatant,
341 ± 33 uL/gram, is greater than the VD of the HIRMAb-ASA fusion protein in the
vascular pellet of brain, 277 ± 30 uL/gram (Table II), which indicates that the majority of
the HIRMAb-ASA fusion protein has traversed the BBB and penetrated the brain
parenchyma. The radioactivity in the post-vascular supernatant represents intact HIRMAbASA fusion protein, and not labeled metabolites, as the TCA precipitation of the postvascular supernatant radioactivity is 95.2 ± 1.4% (Table II).
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The organ uptake of the HIRMAb-ASA fusion protein, expressed as % of injected dose (ID)
per 100 gram wet organ weight, in the Rhesus monkey is listed in Table III for brain and
peripheral organs. The major organs accounting for the removal of the HIRMAb-ASA
fusion protein from plasma are liver and spleen (Table III). The brain uptake of the
HIRMAb-ASA fusion protein is 1.1 ± 0.1 % ID/100 gram brain for the frontal cortex (Table
III). The film autoradiography of the entire primate brain shows that the uptake in the frontal
cortex is representative of the uptake of the whole brain (Figure 5D). The BBB PS product
for the HIRMAb-ASA fusion protein is 4.2 ± 0.3 μL/min/gram.
Film autoradiography of the primate brain removed 2 hours after IV injection shows global
distribution of the HIRMAb-ASA fusion protein throughout brain with higher uptake in gray
matter as compared to white matter (Figure 5D). The frozen brain cortical tissue was also
examined with light microscopic emulsion autoradiography (Figure 7). Panel 7A is an image
taken with 100X magnification and dark field microscopy. The image shows a concentration
of silver grains over brain microvessels, as well as silver grains throughout the parenchyma
of brain. The area of the slide that contains no brain tissue shows very few silver grains,
which indicates the background of the autoradiography is very low. Panel 7B is an image
taken with 200X magnification and dark field microscopy, and the silver grains within the
brain parenchyma are more visible at the higher magnification. Panel 7C was photographed
with a 400X magnification under bright field microscopy, and corresponds to the rectangular
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area of Panel 7B; this image shows silver grains evenly distributed throughout the brain
parenchyma.
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Discussion
The results of this study are consistent with the following conclusions. First, an IgG-ASA
fusion protein has been genetically engineered (Figure 1), and is comprised of two 27 kDa
light chains, and two 124 kDa heavy chains (Figures 2 and 3). Second, the HIRMAb-ASA
fusion protein is bi-functional, and binds the HIR with high affinity (Figure 4) and retains
ASA enzyme activity (Results). Third, the HIRMAb-ASA fusion protein is endocytosed into
MLD fibroblasts and triaged to the lysosomal compartment, as shown by confocal
microscopy (Figure 5C). Fourth, the HIRMAb-ASA fusion protein is rapidly cleared from
plasma with a high systemic volume of distribution (Table I), owing to uptake by peripheral
tissues (Table III). Fifth, the HIRMAb-ASA fusion protein penetrates the brain (Table III),
and film autoradiography shows global distribution of the fusion protein throughout brain
(Figure 5D). Sixth, the HIRMAb-ASA fusion protein penetrates the BBB and distributes to
the post-vascular parenchyma of brain, as shown by the capillary depletion method (Table
II) and light microscopic emulsion autoradiography of monkey brain (Figure 7).
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The nucleotide sequence of the cDNA encoding human ASA was reported by Stein et al
(1989), which enabled the subsequent expression of recombinant ASA. The gene encoding
ASA is mutated in MLD, and ASA enzyme replacement therapy (ERT) is a potential
treatment of MLD. However, the ASA enzyme is a large molecule that does not penetrate
the BBB, and ERT of MLD does not treat the serious CNS manifestations of MLD in either
mouse models (Matzner et al, 2005) or in patients with MLD (Dali et al, 2009). In order to
produce a BBB-penetrating form of ASA, the HIRMAb-ASA fusion protein was engineered.
The ASA monomer is fused to the carboxyl terminus of each heavy chain of a genetically
engineered HIRMAb (Figure 1). The HIRMAb traverses the BBB via receptor-mediated
transport on the endogenous insulin receptor, and carries the fused ASA into the brain from
blood. A biologically active HIRMAb-ASA fusion protein must be a bi-functional fusion
protein and retain both high affinity binding to the insulin receptor and high ASA enzyme
activity. With respect to the insulin receptor function, the affinity of the HIRMAb-ASA
fusion protein for the HIR, as represented by the EC50 of 0.34 ± 0.11 nM, is equal to the
affinity of the HIRMAb alone (Figure 4). The retention of high affinity binding of the fusion
protein for the insulin receptor enables high BBB penetration. The BBB PS product of the
HIRMAb-ASA fusion protein, 4.2 ± 0.3 uL/min/g, is comparable to the BBB PS product of
the murine form of the HIRMAb, 5.4 ± 0.6 uL/min/g (Results), in the Rhesus monkey
(Pardridge et al, 1995). The ASA enzyme activity of the HIRMAb-ASA fusion protein is 20
± 1 units/mg (Results), as compared to the specific activity of recombinant ASA, which is
60 units/mg (Matzner et al, 2005). Based on molecular weights derived from the amino acid
sequence, the molecular weight of the AGT-183 fusion protein half-tetramer is 124,035 Da,
as opposed to the molecular weight of the ASA monomer, 51,900 Da (Methods). Therefore,
on a molar basis, the ASA specific activity of the HIRMAb-ASA fusion protein is
normalized to 48 units/mg protein, which is 80% of the specific activity of recombinant
ASA.
The enzyme activity of ASA is dependent on the post-translational conversion of a cysteine
residue in the amino terminal portion of the enzyme to an N-formylglycine residue, and this
modification is mediated via sulfatase modifying factor 1 (SUMF1) (Schmidt et al, 1995).
Transient expression of ASA in COS cells requires co-transfection of cells with both ASA
and SUMF1 for maximal ASA enzyme activity and secretion (Cosma et al, 2003). However,
the IgG domain drives secretion of the HIRMAb-ASA fusion protein in stably transfected
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CHO cells, and the HIRMAb-ASA fusion protein is secreted with ASA enzyme activity
without co-transfection with the SUMF1 gene (Methods).
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The HIRMAb domain of the HIRMAb-ASA fusion protein cross reacts with the insulin
receptor of Old World primates such as the Rhesus monkey, but does not cross-react with
the insulin receptor of New World monkeys (Pardridge et al, 1995) or the mouse (Zhou et al,
2012). Therefore, in vivo investigations are performed in the Rhesus monkey, and the
present study describes the plasma PK of the HIRMAb-ASA fusion protein in this primate
(Figure 6, Table I). The HIRMAb-ASA fusion protein was radio-iodinated with the [125I]Bolton-Hunter reagent (Methods). This form of radio-labeling is preferred over oxidative
methods, such as chloramine T or Iodogen, because the Bolton-Hunter reagent reaction is
non-oxidative and does not damage the protein. A second advantage of the Bolton-Hunter
reagent over the oxidative methods is that the Bolton-Hunter reagent places a large bulky
(3,5-diiodo, 4-hydroxy-benzene propionyl) substituent on the ε-amino group of surface
lysine residues, whereas the oxidative methods introduce the radioactive iodine at tyrosine
residues. Peripheral degradation of the protein labeled with the oxidative method results in
the release of TCA-soluble metabolite, iodotyrosine, which can cross the BBB on the amino
acid transporter. The lack of BBB transport of blood-borne Bolton-Hunter-conjugated lysine
residue is shown in the present studies. At 120 minutes after IV injection of the [125I]HIRMAb-ASA fusion protein, the plasma radioactivity is 42 ± 2% TCA-precipitable
(Results), whereas the radioactivity in the post-vascular supernatant of brain is 95 ± 1%
TCA-precipitable (Table II). This finding means that radioactivity that distributes to brain
from blood is HIRMAb-ASA fusion protein, and not radiolabeled metabolites.
The HIRMAb-ASA fusion protein is rapidly cleared from plasma (Figure 6), owing to
uptake by peripheral tissues (Table III). The systemic volume of distribution, 233 ± 39 mL/
kg, is 5-fold greater than the central volume of distribution, 46 ± 6 mL/kg (Table I). The
plasma mean residence time in the Rhesus monkey, 59 ± 12 minutes (Table I), is
comparable to the half-time in blood of recombinant ASA in the mouse, 40 minutes
(Matzner et al, 2005). The rapid removal of the HIRMAb-ASA fusion protein is due to
uptake of the protein by peripheral organs (Table III). The most active uptake is via the
liver, 22.4 ± 1.1 % ID/100 grams (Table III). Since the liver weight in an adult Rhesus
monkey is 170 grams (Penniston and Tanumihardjo, 2001), the amount of fusion protein
cleared by the liver is 38% of the injected dose. Similarly, the amount of recombinant ASA
cleared by the liver in the mouse is approximately 40% of injected dose (Matzner et al,
2005).
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ASA does not penetrate the brain in the mouse following an injection dose of 20 mg/kg
(Matzner et al, 2005), because the enzyme, like other large molecules does not cross the
BBB. However, the HIRMAb-ASA fusion protein is rapidly transported into brain in the
Rhesus monkey. The brain uptake is 1.1% ID/100 grams and 0.32 % ID/100 grams in gray
matter and white matter in the cerebrum, respectively (Table III). Brain uptake is expressed
per 100 grams brain, because the brain weight in the Rhesus monkey is 100 grams (Bourne,
1975). The peak brain uptake of fallypride, a lipid soluble small molecule, in the Rhesus
monkey is 4% ID/brain (Christian et al, 2009). Therefore, the brain uptake of the HIRMAbASA fusion protein in the Rhesus monkey is comparable to the brain uptake of a lipid
soluble small molecule.
The HIRMAb-ASA fusion protein distributes to all parts of brain, as shown by the film
autoradiography (Figure 5C). There is higher uptake in gray matter as compared to white
matter, owing to the higher vascular density in gray matter of brain (Lierse and Horstmann,
1959). The HIRMAb-ASA fusion protein penetrates the BBB and distributes to the postvascular parenchyma of brain, as shown by the capillary depletion method (Table II). The
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VD of the fusion protein in the post-vascular supernatant exceeds the VD in the capillary
pellet (Table II), which indicates the majority of fusion protein has penetrated the BBB, and
entered brain parenchyma. The results of the capillary depletion method are confirmed with
light microscopic emulsion autoradiography (Figure 7). The emulsion autoradiography
shows clustering of silver grains within the microvascular compartment (Figure 7A), as well
as uniform distribution of the fusion protein throughout the brain parenchyma (Figure 7B, C,
D). The silver grains in brain parenchyma represent fusion protein, and not metabolites,
since the TCA precipitation of radioactivity in the post-vascular supernatant is 95% (Table
II). Following transport across the BBB, the fusion protein can be endocytosed by brain
cells, since there is high expression of the insulin receptor on cells in the brain (Zhao et al,
1999). The confocal microscopy study shows that the HIRMAb-ASA fusion protein is
endocytosed by target cells and triaged to the lysosomal compartment (Figure 5). Once
inside the lysosomal compartment of the target cell, the lysosomal enzyme domain of the
HIRMAb fusion protein is enzymatically active. Glycosoaminoglycans are reduced in either
Hurler or Hunter fibroblasts following treatments with the respective HIRMAb-lysosomal
enzyme fusion protein (Boado et al, 2008; Lu et al, 2010). The lysosomal inclusion bodies
are reduced in both brain and peripheral organs following the twice-weekly treatment of
Hurler mice with the IgG-lysosomal enzyme fusion protein (Boado et al, 2011).
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The brain uptake of the HIRMAb-ASA fusion protein, 1.1% ID/brain, in the Rhesus monkey
(Table III) allows for estimation of the amount of ASA that might distribute to the human
brain with the IV administration of the HIRMAb-ASA fusion protein. Following the IV
infusion of 2.5 mg/kg in a 50 kg human, the concentration of the fusion protein in brain is
predicted to be 1375 ug fusion protein/brain. This is equivalent to 1.4 ug/gram brain in a
1,000 gram human brain, and 14 ng/mg protein, given 100 mg protein per gram brain. This
level of fusion protein is 14% of the concentration of immunoreactive ASA in the human
brain, which is 100 ng/mg protein (Sevin et al, 2006). However, it is likely that replacement
of only 1–2% of normal ASA enzyme activity in brain will be therapeutic, as is observed in
other lysosomal storage disorders (Muenzer and Fisher, 2004). About 5–20% of the
population has ASA pseudo-deficiency (Fluharty, 2006), where with cellular ASA enzyme
activity is 3–8% of normal without symptoms of MLD (Penzien et al, 1993).
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In summary, the present investigation describes the genetic engineering, expression, and
pharmacokinetics and brain uptake in the Rhesus monkey of the HIRMAb-ASA fusion
protein. The protein is a bi-functional IgG-sulfatase fusion protein, which retains high
affinity binding to the human insulin receptor and high ASA enzyme activity. The fusion
protein is generated from stably transfected CHO cells which are cultivated in serum free
medium. The manufacturing of the HIRMAb-ASA fusion protein will be facilitated by the
use of a protein A capture column in the downstream processing. The HIRMAb-ASA is a
new biological entity for the treatment of the brain in humans with MLD.
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HIR

human insulin receptor

MAb

monoclonal antibody

TfR

transferrin receptor

MLD

Metachromatic Leukodystrophy

ASA

arylsulfatase A

SUMF1

sulfatase modifying factor 1

CHO

Chinese hamster ovary

ERT

enzyme replacement therapy

IV

intravenous

PK

pharmacokinetics

MTH

molecular Trojan horse

HC

heavy chain

LC

light chain

AA

amino acid

SFM

serum free medium

MW

molecular weight

ECD

extracellular domain

FBS

fetal bovine serum

LAMP

lysosomal associated membrane protein

VD

volume of distribution

TCA

trichloroacetic acid

BCA

bicinchoninic acid
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Figure 1.

Structure of the HIRMAb-ASA fusion protein, which is formed by 2 light chains and 2
heavy chains, where the ASA monomer is fused to the carboxy terminus of each heavy
chain. The domains of the light chain include the variable region of the light chain (VL) and
the kappa constant region of the light chain (CL). The domains of the heavy chain include
the variable region of the heavy chain (VH), the 3 sub-domains of the human IgG1 constant
region (CH1, CH2, CH3), and the ASA enzyme.

Biotechnol Bioeng. Author manuscript; available in PMC 2014 February 10.

Boado et al.

Page 14

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Figure 2.
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Reducing SDS-PAGE and Coomassie blue staining of the chimeric HIRMAb and the
HIRMAb-ASA fusion protein. Based on the migration of the molecular weight (MW)
standards, the calculated MW of the light chain is 27 kDa, and the calculated MW of the
heavy chain of the HIRMAb and the HIRMAb-ASA fusion protein is 56 kDa and 124 kDa,
respectively.
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Figure 3.

Western blot with a primary antibody against human IgG (left panel) or human ASA (right
panel). The proteins tested are the chimeric HIRMAb, and the HIRMAb-ASA fusion
protein.
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Figure 4.

Binding to the HIR is saturable for the chimeric HIRMAb and the HIRMAb-ASA fusion
protein. The EC50 was determined by non-linear regression analysis and the value in ng/mL
was converted to nM, based on a molecular weight of 150 kDa for the HIRMAb and a
molecular weight of 300 kDa for the HIRMAb-ASA fusion protein.
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Figure 5.

Panels A, B, and C are confocal micrographs of MLD fibroblasts incubated with the
HIRMAb-ASA fusion protein (10 ug/mL) for 24 hours. The cells were fixed with 100%
methanol and immune stained for confocal microscopy. The fixed cells were stained with a
mouse monoclonal antibody to human lysosomal associated membrane protein (LAMP)-1
(panel A: green channel) and a goat polyclonal antibody to human ASA (panel B: red
channel). The overlap image in panel C shows sequestration of the HIRMAb-ASA fusion
protein within lysosomes. The magnification bar in panel A is 15 microns. Panel D is film
autoradiography of a coronal section of Rhesus monkey brain removed 2 hours after the IV
administration of the [125I]-HIRMAb-ASA fusion protein. The study shows global
distribution of the fusion protein throughout the brain with higher uptake in gray matter as
compared to white matter.
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Figure 6.

The plasma TCA-precipitable radioactivity is expressed as %ID/mL (A) and ng/mL (B) in
the adult Rhesus monkey over a 120 min period after a single IV injection of 55 ug/kg
[125I]-HIRMAb-ASA fusion protein.
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Figure 7.

(A, B, C) Light microscopic emulsion autoradiography of primate brain removed 2 hours
after the IV injection of the [125I]-HIRMAb-ASA fusion protein. Panels A and B dark field
micrographs taken with a 100X and 200X magnifications, respectively. Panel C is bright
field micrograph taken with 400X magnification, and corresponds to the rectangular area in
panel B. The magnification bar in panel C is 11 microns.
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Table I

Pharmacokinetic parameters of the HIRMAb-ASA fusion protein
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parameter

units

A1

%ID/mL

0.243 ± 0.034

value

A2

%ID/mL

0.018 ± 0.003

k1

min-1

0.185 ± 0.024

k2

min-1

0.010 ± 0.002

MRT

min

59 ± 12

Vc

mL/kg

46 ± 6

Vss

mL/kg

233 ± 39

AUC|120

%ID·min/mL

2.57 ± 0.12

AUCss

%ID·min/mL

3.10 ± 0.19

AUCss

ug·min/mL

14.2 ± 0.8

CL

mL/min/kg

3.9 ± 0.2

Parameters computed from the plasma profile in Figure 6.
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Table II

Capillary depletion analysis for brain uptake of the HIRMAb-ASA fusion protein
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Molecule

Brain fraction

VD (μL/g)

HIRMAb-ASA fusion protein

Brain homogenate

526 ± 23

Post-vascular supernatant

341 ± 33

Vascular pellet

277 ± 30

Brain homogenate

20 ± 6

Human IgG1 isotype control

Mean ± S.D. The fusion protein was administered by IV injection, and brain measurements made 120 min following injection. The radioactivity in
the post-vascular supernatant was 95.2 ± 1.4 % precipitable by cold 10% trichloroacetic acid. The homogenate VD for the human IgG1 isotype
control antibody is from Boado and Pardridge (2009).
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Table III

Organ uptake of the HIRMAb-ASA fusion protein in the Rhesus monkey

NIH-PA Author Manuscript

organ

Organ uptake (%ID/100 grams)

Frontal gray

1.08 ± 0.09

Frontal white

0.32 ± 0.10

Cerebellar gray

0.97 ± 0.03

Cerebellar white

0.59 ± 0.07

Choroid plexus

2.19 ± 0.68

liver

22.4 ± 1.1

spleen

14.7 ± 0.3

lung

3.4 ± 0.2

heart

1.1 ± 0.1

fat

0.33 ± 0.01

Skeletal muscle

0.25 ± 0.05

Data are mean ± SD of triplicates samples from one monkey.
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